Skip Navigation

A Phase II Study of XL184 Cabozantinb win Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04079712

Study #:
STUDY00146189

Start Date:
Sep 30, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04079712

View Complete Trial Details & Eligibility at ClinicalTrials.gov